BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-51@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: AbbVie — ABBV-RGX-314 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Pivotal 1 Study of ABBV-RGX-314 (Al
 so Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One
  Time in Participants With nAMD.\nSource: https://clinicaltrials.gov/study
 /NCT04704921\nhttps://catalystbrief.girapphe.com/e/51?lang=en\nNot investm
 ent advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/51?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
